---
title: Precision Medicine for Canine Mammary Gland Tumors
description: Canine mammary tumors represent a diverse landscape of cancers originating from mammary tissue in dogs.
image: https://blog.fidocure.com/hubfs/IMG_0588.jpeg
---

[![FidoCure](https://blog.fidocure.com/hs-fs/hubfs/fidocure_logo.png?width=296&height=68&name=fidocure_logo.png "FidoCure")](https://www.fidocure.com/)

- [Veterinarians](https://fidocure.com/for-veterinarians/) 
    - [Portal Login](https://dvm.fidocure.com/)
    - [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet)
    - [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
    - [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
- [Pet Parents](https://fidocure.com/pet-parents/)
- [About Us](https://fidocure.com/about-us/)
- [How it works](https://fidocure.com/how-it-works/)
- [Find a Clinic](https://fidocure.com/find-a-clinic/)
- [Contact Us](https://fidocure.com/contact-us/)

# Precision Medicine for Canine Mammary Gland Tumors

![FidoCure](https://blog.fidocure.com/hs-fs/hubfs/Screen%20Shot%202023-05-08%20at%2011.54.38%20AM.png?width=45&name=Screen%20Shot%202023-05-08%20at%2011.54.38%20AM.png) 

[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)

[Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.fidocure.com/fidocure-blog/precision-medicine-for-canine-mammary-gland-tumors) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.fidocure.com/fidocure-blog/precision-medicine-for-canine-mammary-gland-tumors) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.fidocure.com/fidocure-blog/precision-medicine-for-canine-mammary-gland-tumors)

Mammary tumors are common in intact female dogs, especially middle-aged and older dogs of smaller breeds like Poodles, Chihuahuas, and Dachshunds, though some larger breeds are also at higher risk. Hormonal exposure plays a key role, with dogs spayed before their first heat cycle having only a 0.5% risk. Treatment typically involves surgical removal, which is potentially curative if the tumor is completely removed. For more invasive, advanced or metastatic cases,. Overall prognosis is quite variable depending upon key clinical features such as histopathologic subtype, tumor size, and metastasis.

![IMG_0586](https://blog.fidocure.com/hs-fs/hubfs/IMG_0586.jpeg?width=1231&height=290&name=IMG_0586.jpeg)

[https://vetgrad.com/show10MinuteTopUp.php?type=&Entity=10MinuteTopUps&ID=138](https://vetgrad.com/show10MinuteTopUp.php?type=&Entity=10MinuteTopUps&ID=138)

**Treatment Options**

Treatment recommendations for mammary  tumors in dogs are often based on factors including grade, size, and metastasis. Surgery is often recommended as the first step in the treatment process because it removes the local disease but also provides valuable information about the tumor. In many cases, patients can do quite well if the tumor can be completely removed with surgery.

For high-grade tumors with evidence of vascular invasion or metastasis, systemic therapy is often recommended. Palladia, an oral anti-cancer drug that targets cancer cells based on a specific mutation, has also been used in the treatment of mammary tumors. Beyond Palladia, there have been additional targeted therapies that may be effective against mammary tumors identified through the FidoCure platform.

Although more extensive studies are needed, Adriamycin (Doxorubicin), a chemotherapy agent used in women with cancer, has shown promise in treating some canine mammary tumors. While generally well-tolerated, potential side effects include lethargy, decreased appetite, vomiting, diarrhea, and decreases in white blood cell and platelet counts. Some oncologists have explored the use of oral chemotherapy in addition to or as an alternative to Adriamycin for patients who do not tolerate injectable chemotherapy. Metronomic chemotherapy, a combination of oral chemotherapy and a non-steroidal anti-inflammatory drug (NSAID), aims to prevent cancer cells from developing their own blood supply and potentially delay disease progression.

**Prognosis**

With early identification and surgical removal, a significant number of canine patients can have a good prognosis with canine mammary tumors. However, patients that have more advanced or aggressive mammary tumors requiring additional therapy   may have a life expectancy of 6 to 12 months following diagnosis. Prognosis can be particularly poor for inflammatory mammary carcinomas or carcinosarcomas.

For the most accurate prognosis and treatment recommendations for your dog with mammary gland tumors, consult your veterinarian or a veterinary oncologist. They can provide personalized guidance based on your dog's specific case, considering factors such as cancer stage, grade, tumor location, and concurrent health issues.

## Related Articles

[![](https://blog.fidocure.com/hubfs/cells.jpg)](https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-insights-from-brca1-mutations)

### [Mammary Carcinoma: Insights from BRCA1 mutations](https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-insights-from-brca1-mutations)

**Genetic Signatures in Canine Mammary Tumors: insights from *BRCA1* mutations**

[Dr. Lucas Rodrigues](https://blog.fidocure.com/fidocure-blog/author/dr-lucas-rodrigues) 

[Read More](https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-insights-from-brca1-mutations)

[![](https://blog.fidocure.com/hubfs/Blog_NasalAdenocarcinoma.png)](https://blog.fidocure.com/fidocure-blog/what-to-know-about-nasal-adenocarcinoma)

### [What to Know About Nasal Adenocarcinoma](https://blog.fidocure.com/fidocure-blog/what-to-know-about-nasal-adenocarcinoma)

Nasal adenocarcinomas are relatively uncommon but represent nearly two-thirds of nasal tumors in dogs, which are locally invasive and have a higher risk of metastasis in...

![FidoCure](https://blog.fidocure.com/hs-fs/hubfs/Screen%20Shot%202023-05-08%20at%2011.54.38%20AM.png?width=45&name=Screen%20Shot%202023-05-08%20at%2011.54.38%20AM.png) 

[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure) 

[Read More](https://blog.fidocure.com/fidocure-blog/what-to-know-about-nasal-adenocarcinoma)

![fc_portal_logo_bw](https://blog.fidocure.com/hubfs/fc_portal_logo_bw.svg)

- [How it Works](https://fidocure.com/how-it-works/)
- [FAQ](https://fidocure.com/faq/)
- [Contact Us](https://fidocurestg.wpengine.com/contact-us/)
- [For Vets](https://fidocure.com/for-veterinarians/)
- [About Us](https://fidocure.com/about-us/)
- [Terms of Service](https://fidocure.com/terms-of-service/)
- [Blog](https://blog.fidocure.com/fidocure-blog)
- [Careers](https://fidocure.com/careers/)
- [Privacy Policy](https://fidocure.com/privacy-policy/)

- <https://www.instagram.com/fidocure/>
- <https://twitter.com/fidocure>
- <https://www.facebook.com/FidoCure/>
- <https://www.pinterest.com/fidocure/>

**FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy. 

© Copyright 2018-2026 One Health Company, All rights reserved

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "FidoCure",
    "url" : "https://blog.fidocure.com/fidocure-blog/author/fidocure"
  },
  "dateModified" : "2024-06-21T21:32:11.584Z",
  "datePublished" : "2024-06-21T21:32:11.000Z",
  "headline" : "Precision Medicine for Canine Mammary Gland Tumors",
  "image" : [ "https://blog.fidocure.com/hubfs/IMG_0588.jpeg" ],
  "mainEntityOfPage" : {
    "@id" : "https://blog.fidocure.com/fidocure-blog/precision-medicine-for-canine-mammary-gland-tumors",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://blog.fidocure.com/hubfs/fidocure_logo.png"
    },
    "name" : "FidoCure"
  }
}
```